Cargando…
L-Asparaginase, Doxorubicin, Vincristine, and Prednisolone (LHOP) Chemotherapy as a First-Line Treatment for Dogs with Multicentric Lymphoma
SIMPLE SUMMARY: Cyclophosphamide exhibits the weakest therapeutic effect compared with vincristine and doxorubicin in the traditional CHOP chemotherapeutic protocol for the treatment of canine lymphoma in previous studies. We want to evaluate the therapeutic effect of a new multi-drug chemotherapy (...
Autores principales: | Lee, Jih-Jong, Liao, Albert Taiching, Wang, Shang-Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388373/ https://www.ncbi.nlm.nih.gov/pubmed/34438662 http://dx.doi.org/10.3390/ani11082199 |
Ejemplares similares
-
Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report
por: Hojo, Nobumasa, et al.
Publicado: (2022) -
Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs
por: Cawley, Jacob R., et al.
Publicado: (2020) -
Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
por: Hornberger, John, et al.
Publicado: (2008) -
Anemia Is a Novel Predictive Factor for the Onset of Severe Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Patients Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Therapy
por: Saito, Takashi, et al.
Publicado: (2019) -
Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone
por: Horvat, Matej, et al.
Publicado: (2018)